NEW YORK (TheStreet) -- The S&P 500 hit 2,000 for the first time in its history but closed short of that mark, up 0.43% to 1,997.92.
On CNBC's "Fast Money" TV show, the trading panel took a closer look at the market.
Steve Grasso, director of institutional sales at Stuart Frankel, advised investors to never "short a dull market." A 10% correction isn't coming anytime soon and the S&P 500 is on track to hit 2,100 by year's end.
Tim Seymour, managing partner of Triogem Asset Management, said he likes financials for three reasons: The sector has lagged the broader market, individual companies are returning to normalized earnings and the economy appears to be accelerating.
Pete Najarian, co-founder of optionmonster.com and trademonster.com, said there doesn't seem to be much fear in the market and many individual financial stocks seem to have room to the upside. He pointed out the bullish options activity in the Financial Select Sector SPDR ETF (XLF) , specifically in the December $24 call options.
Guy Adami, managing director of stockmonster.com, said he continues to like the health care sector. The broader market seems likely to run higher, he added.
The panel was asked what their top buy and sell candidates are:
Najarian likes transport stocks, such as airlines, as well as Goldman Sachs (GS) on the long side. He is a seller of Netflix (NFLX) and is looking for a pullback toward the 200-day simple moving average.
Robyn Karnauskas, biotechnology analyst at Deutsche Bank, said the big theme among biotech companies is creating drugs that address big markets, such as the different liver diseases. She likes Achillion Pharmaceuticals (ACHN) , which is developing treatments for Hepatitis C. A similar peer to ACHN is Idenix Pharmaceuticals (IDIX) , which was recently purchased by Merck (MRK) .
She also likes Intercept Pharmaceuticals (ICPT) , which is developing a treatment for nonalcoholic steatohepatitis. Arrowhead Research (ARWR) could also be an attractive takeover target if its Hepatitis B drug data, which is scheduled to be released this fall, is positive.
Najarian said stocks like Amgen (AMGN) and Celgene have reasonable valuations and strong growth. He likes them on the long side.
Grasso reminded investors that biotech stocks can be volatile. He suggested using the iShares Nasdaq Biotechnology ETF (IBB) to diversify the risks.
Amazon (AMZN) announced that it will purchase Twitch for $970 million. Grasso said he likes the company's move into the gaming and video segment.
Burger King Worldwide (BKW) is in talks to purchase Tim Hortons (THI) and both stocks climbed roughly 20%. Seymour said this is a great deal for Tim Hortons and will benefit Burger King from a tax perspective. Najarian said it will help BKW boost its breakfast and coffee segments as well its exposure in Canada.
Adami said he still finds Burger King cheap, even after Monday's rally. If forced to choose between Burger King and McDonald's (MCD) as investment, Grasso is a buyer of McDonald's.
Dennis Gartman, editor and publisher of The Gartman Letter, was a guest on the show. Despite WTI crude prices falling 12% in the past two months, he said there is more downside ahead, possibly to $85. Until the front month contracts stop trading at lower prices than the back month contracts, the commodity is unlikely to rally.
However, Gartman is a buyer of natural gas, saying that bad news is no longer sending the commodity lower -- a sign that a bottom has been put in. He argued that below $4.00 BTU, natural gas seems attractive. Turning to soft commodities, he said grain rallies should be sold. But due to the bountiful harvest, consumer should enjoy lower meat and crop prices in the future.
Najarian said companies that have both oil and gas operations may be able to withstand falling crude oil prices.
Peter Keith, an analyst at Piper Jaffray, has an overweight rating on shares of Best Buy (BBY) with a $34 price target. He said the company may get roughly 10% of the iPhone market share, which could boost third quarter same-store sales by 1% to 2%. For the fourth quarter, it could result in a same-store sales boost of 2% to 3%, bringing the full-year same-store sales results to the flat to slightly positive range. The stock could "drift" to the high-$30s, he concluded.
Najarian and Seymour said the fundamentals are improving for Best Buy. Grasso added the stock looks to have more upside than downside regarding the technical price action.
BlackBerry (BBRY) climbed 1% and was the first stock on the show's "Pops & Drops" segment. Grasso said investors should sell the rallies in this stock.
U.S. Steel (X) jumped 3% on the back of an upgrade from Credit Suisse. Adami said the stock has had a big run but could get to $43.50 to $45 in the intermediate future.
Ann (ANN) popped 8%. Najarian said the stock is cheap, based on valuation, and could make for an interesting takeover candidate.
Qihoo (QIHU) fell 8%. Seymour said the stock is worth a look on the long side following a strong earnings result.
Najarian pointed out the bullish options activity in shares of QEP Resources (QEP) , specifically the December $37 calls.
Andrew Thompson, co-founder and CEO of Proteus Digital Health, was a guest on the show. The company makes small, swallowable devices to help patients understand how certain drugs work inside their bodies. He said 30% to 50% of medicine is not used properly. The company's two major partners include Novartis (NVS) and Otsuka Holdings (OTSKF) .
However, Najarian said he likes Lorillard for its exposure to e-cigarettes, a $2 billion industry that is rapidly growing.
-- Written by Bret Kenwell in Petoskey, Mich.